Blood-brain barrier disruption in multiple sclerosis.

This review aims to clarify the mechanisms by which the blood-brain barrier (BBB) is disrupted in multiple sclerosis (MS). The study focuses on the interactions between cytokines, chemokines, and immune cells that contribute to BBB failure. The authors seek to understand how these inflammatory mediators affect endothelial cell function and structure. By examining the role of adhesion molecules and activated cerebral endothelial cells (CEC), the study aims to identify key pathways involved in BBB breakdown. The motivation for this work stems from the observation that BBB dysfunction is an early event in MS and is closely linked to disease progression. Researchers are particularly interested in how cytokines like IFN-gamma, TNF-alpha, and IL-1beta influence endothelial integrity. The study also explores indirect mechanisms, such as leukocyte-mediated injury, which may exacerbate BBB damage. This review provides a comprehensive overview of the current evidence on BBB disruption in MS, with the goal of informing future research and treatment strategies.

The authors conducted a literature review to examine the mechanisms of blood-brain barrier (BBB) dysfunction in multiple sclerosis (MS). They focused on the interactions between cytokines, chemokines, and immune cells that contribute to BBB breakdown. The review included analysis of how proinflammatory cytokines affect endothelial cell structure and function. The authors also evaluated the role of adhesion molecules in leukocyte migration across the BBB. They examined the structural features of cerebral endothelial cells (CEC), such as tight junctions and transport systems, to understand how these are altered in MS. The review considered both direct and indirect mechanisms of BBB disruption, including cytokine-dependent effects and leukocyte-mediated injury. The authors synthesized findings from prior studies to identify common pathways and molecular interactions. By integrating data on endothelial cell signaling and immune cell behavior, the review provides a detailed account of the processes involved in BBB failure in MS.

Exposure to proinflammatory cytokines such as IFN-gamma, TNF-alpha, and IL-1beta disrupts the blood-brain barrier (BBB) by disorganizing endothelial cell-cell junctions. These cytokines also reduce the brain's solute barrier and increase leukocyte adhesion and migration. Cerebral endothelial cells (CEC) exposed to these cytokines show increased expression of class II major histocompatibility complex (MHC) molecules. The study found that cytokines promote the shedding of endothelial microparticles (EMP), which may contribute to BBB instability. Adhesion molecules play a critical role in facilitating leukocyte migration across the BBB in MS. The review highlights that cytokine-induced changes in endothelial cell structure and function are central to BBB failure. Indirect mechanisms, such as leukocyte-mediated injury, further exacerbate BBB damage. The findings suggest that both direct and indirect pathways are involved in BBB disruption in multiple sclerosis.

The review concludes that cytokines and chemokines play a central role in the disruption of the blood-brain barrier (BBB) in multiple sclerosis (MS). These molecules directly affect endothelial cell function by altering junctional integrity and increasing permeability. They also promote leukocyte adhesion and migration across the BBB, contributing to immune cell infiltration. The study suggests that cytokine-induced changes in endothelial cell structure and function are key drivers of BBB failure in MS. Indirect mechanisms, such as leukocyte-mediated injury, further compromise the BBB. The findings indicate that both direct and indirect pathways are involved in BBB disruption. The authors propose that understanding these mechanisms may lead to new therapeutic strategies for MS. The review emphasizes the need for further research to clarify the precise interactions between cytokines, immune cells, and endothelial cells in MS.